Arca
Skip to content
Tools
Tools

Overactive urinary bladder

Drug research and approvals for overactive urinary bladder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 77 studies of overactive urinary bladder are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.

  • Recruiting worldwide: 77
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 77 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

9 approved, 7 in phase 3, 16 in phase 2, 7 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Mirabegron, Tolterodine, Solifenacin, Fesoterodine, Oxybutynin, Vibegron, Darifenacin, Trospium, Botulinum toxin type a

Onabotulinumtoxina
Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Ritobegron
Phase 3 Beta-3 adrenergic receptor agonist
Imidafenacin
Phase 3 Muscarinic acetylcholine receptor M3 antagonist
Incobotulinumtoxina
Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Lidocaine
Phase 3 Sodium channel alpha subunit blocker
Dimethyl sulfoxide
Phase 3 Unknown
Solabegron
Phase 2 Beta-3 adrenergic receptor agonist
Burapitant
Phase 2 Neurokinin 1 receptor antagonist
Tarafenacin
Phase 2 Muscarinic acetylcholine receptor M3 antagonist
Casopitant
Phase 2 Neurokinin 1 receptor antagonist
Eliapixant
Phase 2
Desmopressin
Phase 2 Vasopressin receptor agonist
Estrogens, conjugated
Phase 2 Estrogen receptor agonist
Vardenafil
Phase 2 Phosphodiesterase 5A inhibitor
Pregabalin
Phase 2 Voltage-gated calcium channel modulator
Afacifenacin
Phase 2 Muscarinic acetylcholine receptor antagonist
Dexmecamylamine
Phase 2 Neuronal acetylcholine receptor; alpha4/beta2 antagonist
ONO-8539
Phase 2 Prostanoid EP1 receptor antagonist
Gisadenafil
Phase 2 Phosphodiesterase 5A inhibitor
Warfarin
Phase 1 Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
Propantheline
Phase 1 Muscarinic acetylcholine receptor M3 antagonist
Fluconazole
Phase 1 Cytochrome P450 51 inhibitor
Cephalexin anhydrous
Phase 1 Bacterial penicillin-binding protein inhibitor
Levofloxacin anhydrous
Phase 1 DNA gyrase inhibitor
Sunobinop
Phase 1

How Its Trials Ended

794 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 188 whose ending is known, 51% met their primary endpoint, 2% missed it and 47% stopped early.

  • Completed, result not reported38649%
  • Status unknown11314%
  • Ongoing10713%
  • Met its primary endpoint9612%
  • Stopped: other or unclear405%
  • Stopped: enrollment or feasibility304%
  • Stopped: lack of efficacy61%
  • Stopped: sponsor or business decision51%
  • Missed its primary endpoint41%
  • Stopped: safety41%
  • Stopped: funding30%

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.